Obesity Epidemic in India

UPSC Syllabus: Gs Paper 2- Issues relating to development and management of Social Sector/Services relating to Health.

Introduction

India is facing a growing obesity crisis linked with rising metabolic diseases like diabetes and hypertension. Nearly one-fourth of the population is overweight or obese, with childhood obesity rising rapidly. Alongside lifestyle changes, there is an increasing shift toward pharmaceutical solutions, raising concerns about medicalisation, market influence, and neglect of root causes in addressing long-term public health.

What is Obesity?

1. Meaning: Obesity is defined as abnormal or excessive fat accumulation that increases health risks and leads to diseases like diabetes and heart conditions.
2. Measurement through BMI: The most common screening tool is Body Mass Index (BMI), used to classify overweight and obesity levels.
3. Health risks associated: It increases the risk of diabetes, hypertension, cardiovascular diseases, and certain cancers, making it a major public health issue.

Rising Burden and Changing Epidemiology

1. Increasing prevalence in population: Nearly 25% of Indians are overweight or obese, showing a sharp rise over recent decades.
2. Gender-wise increase: Obesity in women increased from 1.2% (1990) to 9.8% (2022) with 44 million women affected, while 26 million men are also obese.
3. Childhood obesity surge: Obese boys increased from 0.2 million to 7.3 million, and girls from 0.2 million to 5.2 million, showing a serious trend.
4. High burden of related diseases: Around 1 in 10 adults has diabetes and 1 in 3 has hypertension, along with fatty liver disease.
5. Thin-fat phenotype in Indians: Indians tend to have higher body fat despite lean appearance, increasing health risks even at lower BMI.

Underlying Causes of Obesity in India

1. Unhealthy lifestyle patterns: Lack of physical activity, poor sleep, and stress have increased due to urban lifestyles and work patterns.
2. Shift in dietary habits: People are consuming more processed, high fat, salt, and sugar foods, while spending less on nutritious items like cereals and pulses.
3. Growth of ultra-processed food industry: The sector grew at around 13% annually (2011–2021), increasing unhealthy food consumption.
4. Urbanisation and income rise: Higher income and urban living have led to increased intake of calorie-rich foods and reduced activity levels.
5. Low awareness and weak implementation: Limited awareness of healthy diets and weak enforcement of FSSAI guidelines have worsened the situation.
6. Obesity no longer linked to wealth: Cheap junk food has made obesity common across all sections, not only among the rich.
7. Generational dietary impact: Poor dietary habits of mothers affect children, creating a cycle of obesity across generations.
8. Shift from undernutrition to silent acceptance: Earlier, excess weight was seen as a sign of prosperity in a society shaped by undernutrition, which delayed recognition of obesity as a serious problem.

Impacts of Obesity in India

1. Health burden of diseases: Obesity increases risk of non-communicable diseases (NCDs) like diabetes, cancer, and heart disease.
2. Child development issues: Obesity leads to poor physical and cognitive development in children.
3. Psychosocial effects: Individuals face body image issues and mental stress due to social stigma.
4. Economic impact: Obesity causes loss of productivity, absenteeism, and higher healthcare costs.
5. Pressure on healthcare system: Rising NCDs increase strain on the already fragile public health system.
6. Social inequality dimension: Vulnerable groups and women are more affected, leading to greater health and economic disparities.

Pharmaceuticalisation of Obesity

1. Trigger indicating institutional shift: Recent actions linking employment conditions with BMI show how obesity is being treated as a measurable risk, reinforcing the push toward medical solutions.
2. Rise of anti-obesity drugs: Drugs like tirzepatide and semaglutide have expanded rapidly, creating a large treatment market.
3. Shift from lifestyle to medication: Obesity is increasingly treated through medicines instead of behavioural changes.
4. Commercial expansion of healthcare: The success of these drugs shows the rise of a profitable therapeutic industry.
5. Surrogate advertising practices: Companies use indirect promotions like awareness campaigns, influencers, and sponsored content to shape demand.
6. Delayed regulatory response: Government restrictions on such promotions came late, allowing widespread influence.
7. Blurring science and marketing: New drugs are presented as breakthroughs, while their uncertainties receive less attention, making it difficult to separate scientific progress from market-driven promotion.

Major Concerns Related to Pharmaceuticalisation of Obesity

1. Loss of muscle mass (sarcopenia): Around 25–40% of weight loss is muscle, which weakens strength and long-term health.
2. Risk of incomplete treatment: Appetite suppression without proper diet and exercise can harm metabolic resilience.
3. Cycle of drug dependency: Use of one drug leads to side effects, which require new drugs, creating a continuous cycle.
4. New markets for side effects: Drugs for treating sarcopenia are already in development, expanding the medical market further.
5. Rapid changes in clinical guidelines: Faster inclusion of drugs raises questions about long-term evidence and neutrality.
6. Neglect of root causes: Growth of ultra-processed foods continues, while policy measures like warning labels remain delayed.
7. Paradox of the system: One sector promotes unhealthy consumption, another treats the resulting diseases, and a third manages side effects, creating a cycle that is efficient for markets but weak for public health.
8. Expansion of medicalisation in daily life: Obesity is increasingly treated through continuous medical intervention, showing how healthcare is moving into everyday lifestyle issues.

Way Forward

1. Rebalancing health approach: There is a need to shift focus from quick medical fixes to long-term lifestyle changes and preventive care.
2. Focus on lifestyle changes: Healthy diet, physical activity, proper sleep, and stress control must be the primary approach.
3. Use medicines as support only: Drugs should act as adjuncts, not substitutes, for long-term health improvement.
4. Ensure transparency in treatment: Risks of new therapies must be clearly communicated to patients.
5. Strengthen regulation: Stronger control over surrogate advertising and promotions is required.
6. Address food system issues: Policies must focus on controlling ultra-processed food growth and improving nutrition awareness.
7. Reinforce ethical medical practice: Medical professionals should ensure evidence-based and unbiased decisions.

Conclusion

Obesity in India reflects a shift from lifestyle imbalance to a system shaped by market-driven medicalisation. While medicines offer short-term relief, they risk creating dependency and ignoring root causes. A balanced approach that prioritises prevention, lifestyle change, and ethical medical practice is essential to ensure long-term health and avoid excessive reliance on pharmaceutical solutions.

Question for practice:

Examine how the rising obesity epidemic in India reflects a shift towards pharmaceuticalisation and what concerns it raises for public health.

Source: The Hindu